Alnylam Pharmaceuticals, Inc. $ALNY Stock: Machina Capital S.A.S. Grows Stake

Machina Capital S.A.S. lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 236.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,857 shares of the biopharmaceutical company’s stock after acquiring an additional 5,522 shares during the period. Machina Capital S.A.S.’s holdings in Alnylam Pharmaceuticals were worth $1,939,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Wellington Management Group LLP raised its position in shares of Alnylam Pharmaceuticals by 9.0% during the second quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock worth $635,296,000 after purchasing an additional 174,482 shares during the period. Legal & General Group Plc bought a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Alnylam Pharmaceuticals by 7.4% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company’s stock worth $219,104,000 after acquiring an additional 50,329 shares during the last quarter. Pictet Asset Management Holding SA boosted its position in Alnylam Pharmaceuticals by 77.7% during the 3rd quarter. Pictet Asset Management Holding SA now owns 495,168 shares of the biopharmaceutical company’s stock worth $122,783,000 after acquiring an additional 216,555 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $148,128,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $156.65 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $149.18 and a one year high of $479.79. The company has a market cap of $20.98 billion, a price-to-earnings ratio of 8.13 and a beta of 0.42. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.48 and a quick ratio of 2.43. The firm has a 50 day simple moving average of $221.24 and a 200 day simple moving average of $276.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same quarter last year, the business earned $2.90 EPS. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.85 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of the business’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the transaction, the executive vice president owned 12,807 shares in the company, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Truist Financial cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price objective for the company from $315.00 to $225.00 in a report on Monday, November 2nd. Citigroup dropped their price objective on shares of Alnylam Pharmaceuticals from $340.00 to $320.00 and set a “buy” rating on the stock in a research report on Wednesday, October 14th. Sanford C. Bernstein lowered Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $376.00 to $199.00 in a research note on Friday, October 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, October 29th. Finally, Oppenheimer dropped their price objective on Alnylam Pharmaceuticals from $350.00 to $320.00 and set an “outperform” rating for the company in a report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $305.86.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.